Regencell Bioscience Holdings Ltd (RGC) — Strategic Asset Allocation Index
Regencell Bioscience Holdings Ltd (RGC) has a Strategic Asset Allocation Index of 8.5% as of June 2022. Strategic assets (PP&E of $1.46 Million plus long-term investments of $-) total $1.46 Million, measured against net assets of $17.08 Million. A higher index reflects capital-intensive or investment-heavy strategies where strategic assets dominate the equity base.
SAAI
Strategic Assets
PP&E
Net Assets
Regencell Bioscience Holdings Ltd Strategic Asset Allocation Index (2022–2022)
This chart shows how Regencell Bioscience Holdings Ltd's Strategic Asset Allocation Index has evolved across 1 annual periods from 2022 to 2022. As of June 2022, the index stands at 8.5%, representing strategic assets of $1.46 Million against net assets of $17.08 Million USD. Explore RGC cash generation efficiency to assess how effectively this company generates cash.
Annual Strategic Asset Allocation Index for Regencell Bioscience Holdings Ltd (2022–2022)
The table below presents the year-by-year Strategic Asset Allocation Index for Regencell Bioscience Holdings Ltd from 2022 to 2022, covering 1 annual filings. Each row shows PP&E, long-term investments, strategic assets combined, net assets, the index percentage, and the change in percentage points compared to the prior year. For the full company profile including market capitalisation, see market value of Regencell Bioscience Holdings Ltd.
| Year | SAAI | Strategic Assets (USD) | PP&E | LT Investments | Net Assets | Change (pp) |
|---|---|---|---|---|---|---|
| 2022 | 8.5% | $1.46 Million | $1.46 Million | $- | $17.08 Million | — |